Press Releases Year None202320222021 June 5, 2023 NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients June 3, 2023 NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 May 31, 2023 NewAmsterdam Pharma to Present at Jefferies Healthcare Conference May 23, 2023 NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 May 8, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights April 24, 2023 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia April 3, 2023 NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors March 31, 2023 NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update March 1, 2023 NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference February 9, 2023 NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
June 5, 2023 NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
June 3, 2023 NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
May 8, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
April 24, 2023 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
March 31, 2023 NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
